Wall Street brokerages forecast that Five Prime Therapeutics, Inc. (NASDAQ:FPRX) will post earnings per share of ($1.18) for the current quarter, Zacks reports. Two analysts have issued estimates for Five Prime Therapeutics’ earnings, with estimates ranging from ($1.28) to ($0.98). Five Prime Therapeutics posted earnings of ($0.49) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 140.8%. The firm is expected to report its next quarterly earnings report on Thursday, August 3rd.
According to Zacks, analysts expect that Five Prime Therapeutics will report full year earnings of ($4.68) per share for the current fiscal year, with EPS estimates ranging from ($4.91) to ($4.26). For the next fiscal year, analysts anticipate that the firm will report earnings of ($4.97) per share, with EPS estimates ranging from ($6.00) to ($3.56). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Five Prime Therapeutics.
Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings results on Thursday, May 4th. The biotechnology company reported ($1.21) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.96) by $0.25. Five Prime Therapeutics had a negative return on equity of 21.81% and a negative net margin of 250.98%. The company had revenue of $10.13 million for the quarter, compared to analyst estimates of $6.05 million. During the same period in the prior year, the business earned ($0.49) earnings per share. Five Prime Therapeutics’s revenue for the quarter was up 55.8% compared to the same quarter last year.
A number of research analysts have issued reports on the company. Jefferies Group LLC reiterated a “buy” rating and set a $55.00 price target on shares of Five Prime Therapeutics in a research report on Thursday, June 8th. Zacks Investment Research lowered Five Prime Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, May 2nd. TheStreet lowered Five Prime Therapeutics from a “c” rating to a “d+” rating in a research report on Monday, March 20th. ValuEngine upgraded Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd. Finally, Cowen and Company assumed coverage on Five Prime Therapeutics in a research report on Friday, March 24th. They set an “outperform” rating for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $60.83.
A number of hedge funds and other institutional investors have recently made changes to their positions in FPRX. Creative Planning raised its position in shares of Five Prime Therapeutics by 0.8% in the second quarter. Creative Planning now owns 6,744 shares of the biotechnology company’s stock worth $203,000 after buying an additional 54 shares during the period. Bank of America Corp DE raised its stake in shares of Five Prime Therapeutics by 5.8% in the first quarter. Bank of America Corp DE now owns 18,558 shares of the biotechnology company’s stock valued at $671,000 after buying an additional 1,025 shares during the period. American International Group Inc. raised its stake in shares of Five Prime Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 16,614 shares of the biotechnology company’s stock valued at $601,000 after buying an additional 1,100 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Five Prime Therapeutics by 7.0% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,030 shares of the biotechnology company’s stock valued at $724,000 after buying an additional 1,302 shares during the period. Finally, Teachers Advisors LLC raised its stake in shares of Five Prime Therapeutics by 0.7% in the fourth quarter. Teachers Advisors LLC now owns 238,428 shares of the biotechnology company’s stock valued at $11,948,000 after buying an additional 1,558 shares during the period. Institutional investors own 85.92% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Expected to Post Earnings of -$1.18 Per Share” was originally posted by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.tickerreport.com/banking-finance/2723599/five-prime-therapeutics-inc-nasdaqfprx-expected-to-post-earnings-of-1-18-per-share.html.
Shares of Five Prime Therapeutics (NASDAQ:FPRX) traded up 1.50% during midday trading on Friday, hitting $29.72. The company had a trading volume of 178,474 shares. Five Prime Therapeutics has a 12 month low of $26.65 and a 12 month high of $60.98. The stock’s 50-day moving average price is $29.94 and its 200-day moving average price is $39.01. The company’s market cap is $829.10 million.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.